New Zealand health officials said on Wednesday that doctors will stop prescribing puberty blockers to children who identify as transgender. The change takes effect on Dec. 19, after the health ministry explained that there is no “high‑quality evidence” showing clear benefits or risks of the drug.
The medication – a gonadotropin‑releasing hormone analogue – has been used for gender‑affirming care. It can pause puberty, giving transgender and gender‑diverse teens time to make decisions about their bodies. It is also used for medical conditions such as early‑onset puberty, endometriosis and prostate cancer.
Existing patients will still be able to continue their treatment. According to the ministry, 113 people were using puberty blockers in 2023, down from 140 in 2021.
The decision has drawn sharp criticism. “The ban will worsen mental health, increase suicidality and dysphoria for gender‑diverse children and young people,” said Elizabeth McElrea, vice‑president of the Professional Association for Transgender Health Aotearoa. Critics argue that medical decisions should remain in the hands of patients and their doctors.
New Zealand’s move follows similar bans elsewhere. England’s National Health Service cut off puberty blockers for minors more than a year ago, limiting use only in exceptional circumstances. In the United States, transgender medical care for minors has been available for over a decade and is backed by major medical associations. Some Republican‑led states have already banned puberty blockers and other treatments for transgender teens.
Health Minister Simeon Brown said the ruling was based on a lack of solid evidence. The rule does not affect adults who need the medication for other health conditions. The change highlights the global debate over how best to support transgender youth while protecting medical safety.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
